Key facts
- This page summarizes Vikas Sinha's Form 4 filing for Allovir, Inc. (KLRS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Feb 2025, 16:15.
Vikas Sinha - 21 Feb 2025 Form 4 Insider Report for Allovir, Inc. (KLRS)
- Reporting relationship
- Officer Title: President, Chief Financial Officer and Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- KLRS
- Reported as of
- 21 Feb 2025
- Net transaction value
- -$3,053
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2025, 16:15:10 UTC
- Prior SEC filing
- 27 Jan 2025
- Next SEC filing
- 29 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brett Hagen, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Vikas Sinha filed Form 4 for Allovir, Inc. (KLRS) on 24 Feb 2025.
Change
- Previous filing in this sequence was filed on 27 Jan 2025.
- Current net transaction value: -$3,053.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALVR
transaction
Common Stock
Sale
- Transaction value
- $3,053
- Shares
- -303
- Change %
- -0.61%
- Price
- $10.08
- Shares after
- 49,129
- Date
- 21 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
ALVR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 724,989
- Date
- 21 Feb 2025
- Ownership
- See footnote
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F3
Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
SEC remarks
Officer Title: President, Chief Financial Officer and Chief Executive Officer